Celgene Stock Price, News & Analysis (NASDAQ:CELG)

$106.00 1.42 (1.36 %)
(As of 01/16/2018 02:51 AM ET)
Previous Close$104.58
Today's Range$104.31 - $106.43
52-Week Range$94.55 - $147.17
Volume8.75 million shs
Average Volume7.77 million shs
Market Capitalization$83.46 billion
P/E Ratio25.00
Dividend YieldN/A
Beta1.77

About Celgene (NASDAQ:CELG)

Celgene logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CELG
CUSIP15102010
Phone+1-908-6739000

Debt

Debt-to-Equity Ratio1.31%
Current Ratio3.65%
Quick Ratio3.52%

Price-To-Earnings

Trailing P/E Ratio25
Forward P/E Ratio15.84
P/E Growth0.68

Sales & Book Value

Annual Sales$11.23 billion
Price / Sales7.43
Cash Flow$6.02 per share
Price / Cash17.60
Book Value$8.51 per share
Price / Book12.46

Profitability

Trailing EPS$4.24
Net Income$2.00 billion
Net Margins27.36%
Return on Equity63.80%
Return on Assets17.45%

Miscellaneous

Employees7,132
Outstanding Shares787,320,000

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene shares split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were distributed to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) posted its earnings results on Thursday, October, 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The biopharmaceutical company earned $3.29 billion during the quarter, compared to analysts' expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $1.58 EPS. View Celgene's Earnings History.

When will Celgene make its next earnings announcement?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, January, 25th 2018. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY18 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of $8.70-8.90 for the period, compared to the Thomson Reuters consensus estimate of $8.70. The company issued revenue guidance of $14.4-14.8 billion, compared to the consensus revenue estimate of $14.84 billion.Celgene also updated its Q4 guidance to $2.00 EPS.

Where is Celgene's stock going? Where will Celgene's stock price be in 2018?

30 analysts have issued 1-year price objectives for Celgene's shares. Their forecasts range from $91.00 to $166.00. On average, they anticipate Celgene's stock price to reach $131.21 in the next year. View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:

  • 1. According to Zacks Investment Research, "Celgene’s Revlimid continue to outperform driven by further market share increases in newly diagnosed myeloma and the continued increase in treatment duration. Pomalyst and Abraxane also performed well. The approval of Idhifa for relapsed and/or refractory acute myeloid leukemia has further boosted the company’s portfolio. However, Celgene is highly dependent on Revlimid. Celgene suffered a setback as the label expansion study on lead drug Revlimid failed in phase III. The drug’s label expansion would have boosted its sales potential. Additionally, the deep yet persistently slow growth of the psoriatic arthritis and psoriasis markets, especially during the entire third quarter, has led to a weak performance of Otezla. Consequently, the company also reduced its annual guidance. Shares have underperformed the industry in the last six months. " (1/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "CELG will record a pretax charge of approximately $411 million in 4Q17 in relation to the wind-down of the GED-0301 program, announced in October 2017." (12/29/2017)
  • 3. Cann analysts commented, "We conducted a physician survey to evaluate the current treatment preferences and satisfaction with available therapies, along with expectations for therapies in clinical development. Our report (published 11/21/17), Multiple Sclerosis Survey: Unmet Need Persists Despite Several Approved Treatment Options, concluded that there is a meaningful unmet need in MS treatment and a high level of interest in Ozanimod if FDA-approved. We conclude that approximately 80% of the neurologists surveyed are unsatisfied with the therapies available to them. The survey showed that 40.4% of patients are being treated with oral therapy. The surveyed neurologists replied that they would, on average, put 23.8% of their patients on a newly approved therapy they had selected from the survey." (11/22/2017)
  • 4. BTIG Research analysts commented, "After mkt-close on Thursday, Celgene announced termination of the Phase 3 studies (REVOLVE and SUSTAIN) for mongersen in the treatment of Crohn’s disease, and that the Phase 3 DEFINE study will not be initiated. Termination of the programs follow the recommendation of the Data Monitoring Committee (DMC) who indicated futility of mongersen in producing a clinical benefit. Based on the announcement, we have taken our 2023 mongersen estimates to zero from $215m previously, versus consensus at ~$1bn." (10/22/2017)

Are investors shorting Celgene?

Celgene saw a increase in short interest in the month of December. As of December 15th, there was short interest totalling 13,477,756 shares, an increase of 17.1% from the November 30th total of 11,514,288 shares. Based on an average daily volume of 5,987,801 shares, the days-to-cover ratio is currently 2.3 days. Currently, 1.7% of the shares of the stock are sold short.

Who are some of Celgene's key competitors?

Who are Celgene's key executives?

Celgene's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board (Age 62)
  • Scott A. Smith, President, Chief Operating Officer (Age 55)
  • Mark J. Alles, Chief Executive Officer, Director (Age 58)
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President (Age 61)
  • Terrie Curran, President, Global Inflammation & Immunology Franchise (Age 48)
  • Michael F. Pehl, President, Hematology & Oncology (Age 52)
  • Rupert J Vessey, President - Research and Early Development (Age 52)
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary (Age 49)
  • Michael D. Casey, Lead Independent Director (Age 71)
  • Michael W. Bonney, Director (Age 59)

Who owns Celgene stock?

Celgene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bristol John W & Co. Inc. NY (0.07%), LGT Capital Partners LTD. (0.05%), Nisa Investment Advisors LLC (0.03%), Stock Yards Bank & Trust Co. (0.02%), DnB Asset Management AS (0.02%) and Exxonmobil Investment Management Inc. TX (0.02%). Company insiders that own Celgene stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Who sold Celgene stock? Who is selling Celgene stock?

Celgene's stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Atalanta Sosnoff Capital LLC, Chesley Taft & Associates LLC, Nisa Investment Advisors LLC, Exxonmobil Investment Management Inc. TX, Private Capital Advisors Inc., Covenant Asset Management LLC and Sheets Smith Wealth Management. Company insiders that have sold Celgene company stock in the last year include Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Insider Buying and Selling for Celgene.

Who bought Celgene stock? Who is buying Celgene stock?

Celgene's stock was acquired by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., WIM Asset Management HK Ltd, Bristol John W & Co. Inc. NY, DnB Asset Management AS, Capital Investment Services of America Inc., Stock Yards Bank & Trust Co., Neville Rodie & Shaw Inc. and Hikari Power Ltd. Company insiders that have bought Celgene stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene.

How do I buy Celgene stock?

Shares of Celgene can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of Celgene stock can currently be purchased for approximately $106.00.

How big of a company is Celgene?

Celgene has a market capitalization of $83.46 billion and generates $11.23 billion in revenue each year. The biopharmaceutical company earns $2.00 billion in net income (profit) each year or $4.24 on an earnings per share basis. Celgene employs 7,132 workers across the globe.

How can I contact Celgene?

Celgene's mailing address is 86 Morris Ave, SUMMIT, NJ 07901-3915, United States. The biopharmaceutical company can be reached via phone at +1-908-6739000 or via email at [email protected]


MarketBeat Community Rating for Celgene (CELG)

Community Ranking:  3.9 out of 5 (star star star)
Outperform Votes:  1,679 (Vote Outperform)
Underperform Votes:  492 (Vote Underperform)
Total Votes:  2,171
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celgene (NASDAQ:CELG) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.532.652.732.73
Ratings Breakdown: 1 Sell Rating(s)
12 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
2 Sell Rating(s)
3 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
20 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $131.21$136.78$152.30$141.27
Price Target Upside: 24.38% upside26.41% upside11.41% upside5.06% upside

Celgene (NASDAQ:CELG) Consensus Price Target History

Price Target History for Celgene (NASDAQ:CELG)

Celgene (NASDAQ:CELG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/10/2018GuggenheimReiterated RatingBuy$147.00LowView Rating Details
1/8/2018SunTrust BanksSet Price TargetBuy$127.00MediumView Rating Details
1/8/2018Credit Suisse GroupSet Price TargetBuy$125.00MediumView Rating Details
1/8/2018Stifel NicolausSet Price TargetBuy$130.00MediumView Rating Details
1/8/2018Deutsche BankSet Price TargetHold$110.00LowView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$166.00HighView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetHold$112.00HighView Rating Details
1/5/2018MizuhoSet Price TargetBuy$128.00LowView Rating Details
1/5/2018Bank of AmericaDowngradeBuy -> Neutral$104.68 -> $120.00MediumView Rating Details
1/4/2018Royal Bank of CanadaReiterated RatingBuy$147.00HighView Rating Details
12/27/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$121.00HighView Rating Details
12/22/2017Leerink SwannReiterated RatingBuy$120.00LowView Rating Details
12/22/2017BMO Capital MarketsReiterated RatingBuy$147.00LowView Rating Details
12/22/2017CitigroupReiterated RatingHoldMediumView Rating Details
12/10/2017Piper Jaffray CompaniesReiterated RatingHoldHighView Rating Details
12/8/2017Atlantic SecuritiesUpgradeNeutral -> OverweightHighView Rating Details
11/22/2017CannReiterated RatingBuy$166.00N/AView Rating Details
11/16/2017Canaccord GenuitySet Price TargetBuy$140.00N/AView Rating Details
10/27/2017JPMorgan Chase & Co.Set Price TargetBuy$123.00N/AView Rating Details
10/27/2017BarclaysReiterated RatingEqual Weight -> Equal Weight$135.00 -> $105.00N/AView Rating Details
10/27/2017Goldman Sachs GroupReiterated RatingSell$116.00 -> $91.00N/AView Rating Details
10/27/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
10/27/2017JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
10/27/2017Robert W. BairdReiterated RatingHold$103.00N/AView Rating Details
10/26/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
10/22/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/20/2017William BlairReiterated RatingOutperformN/AView Rating Details
10/16/2017Jefferies GroupReiterated RatingBuy$160.00N/AView Rating Details
9/12/2017CowenReiterated RatingBuy$150.00LowView Rating Details
7/31/2017ArgusUpgradeHold -> Buy$96.93 -> $160.00LowView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
4/28/2016Raymond James FinancialReiterated RatingBuyN/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Celgene (NASDAQ:CELG) Earnings History and Estimates Chart

Earnings by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018$1.94N/AView Earnings Details
10/26/2017Q3 2017$1.87$1.91$3.42 billion$3.29 billionViewN/AView Earnings Details
7/27/20176/30/2017$1.61$1.82$3.23 billion$3.27 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
10/28/2010Q3 2010$0.32$0.32ViewN/AView Earnings Details
7/29/2010Q2 2010$0.30$0.30ViewN/AView Earnings Details
4/29/2010Q1 2010$0.28$0.27ViewN/AView Earnings Details
1/28/2010Q4 2009$0.29$0.29ViewN/AView Earnings Details
10/22/2009Q3 2009$0.25$0.25ViewN/AView Earnings Details
7/23/2009Q2 2009$0.21$0.20ViewN/AView Earnings Details
4/30/2009Q1 2009$0.20$0.16ViewN/AView Earnings Details
1/29/2009Q4 2008$0.19$0.19ViewN/AView Earnings Details
10/23/2008Q3 2008$0.18$0.17ViewN/AView Earnings Details
7/24/2008Q2 2008$0.16$0.15ViewN/AView Earnings Details
5/8/2008Q1 2008$0.16$0.17ViewN/AView Earnings Details
1/31/2008Q4 2007$0.15$0.15ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Celgene (NASDAQ:CELG) Earnings Estimates

Current Year EPS Consensus Estimate: $6.69 EPS
Next Year EPS Consensus Estimate: $8.01 EPS

Dividends

Dividend History for Celgene (NASDAQ:CELG)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celgene (NASDAQ CELG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 79.85%
Insider Trades by Quarter for Celgene (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene (NASDAQ CELG) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/25/2017Terrie CurranInsiderSell1,727$143.89$248,498.033,925View SEC Filing  
9/12/2017Gilla KaplanDirectorSell9,250$141.56$1,309,430.0085,551View SEC Filing  
9/5/2017Michael D CaseyDirectorSell9,250$139.03$1,286,027.509,250View SEC Filing  
8/10/2017Ernest MarioDirectorSell18,506$130.52$2,415,403.1269,424View SEC Filing  
8/2/2017Gilla KaplanDirectorSell7,500$134.52$1,008,900.0076,301View SEC Filing  
6/26/2017James J LoughlinDirectorSell18,500$133.57$2,471,045.0032,877View SEC Filing  
6/22/2017Michael A FriedmanDirectorSell10,000$132.50$1,325,000.005,000View SEC Filing  
6/22/2017Robert J HuginInsiderSell175,970$134.14$23,604,615.801,033,909View SEC Filing  
6/21/2017Michael D CaseyDirectorSell9,250$133.05$1,230,712.509,250View SEC Filing  
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.304,004View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.0032,169View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.3973,109View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00778View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.0018,600View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.5650,000View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.0031,332View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.4072,142View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.0042,919View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.001,022,201View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.001,122,201View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.2872,518View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.0019,785View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.0082,449View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.6888,485View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.0088,485View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.1625,705View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00100,671View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.7850View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.0022,688View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.7815,349View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celgene (NASDAQ CELG) News Headlines

Source:
DateHeadline
David Rolfe Comments on CelgeneDavid Rolfe Comments on Celgene
finance.yahoo.com - January 13 at 9:47 AM
Top VC deals: Jaguar backs robo-taxis, Google buys Redux, Celgene buys new cancer drugsTop VC deals: Jaguar backs robo-taxis, Google buys Redux, Celgene buys new cancer drugs
www.cnbc.com - January 12 at 10:49 PM
Celgene Co. (CELG) Given Consensus Recommendation of "Buy" by AnalystsCelgene Co. (CELG) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 12 at 3:52 PM
Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018Wait, It Costs How Much? Biotech Balances Optimism, Uncertainty For 2018
finance.yahoo.com - January 12 at 9:55 AM
Here's What Celgene's Management Just Said About Its FutureHere's What Celgene's Management Just Said About Its Future
finance.yahoo.com - January 11 at 10:10 AM
Key Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare ConferenceKey Takeaways from Pfizer & 3 Other Drug Stocks at Healthcare Conference
finance.yahoo.com - January 11 at 10:10 AM
Yes, There’s Hope for Celgene. Really.Yes, There’s Hope for Celgene. Really.
www.barrons.com - January 10 at 9:58 AM
[$$] Impact Biomedicines Turns Sanofi Drug Into $1.1 Billion Success[$$] Impact Biomedicines Turns Sanofi Drug Into $1.1 Billion Success
finance.yahoo.com - January 10 at 9:58 AM
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in FocusBiotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
finance.yahoo.com - January 10 at 9:58 AM
Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic OncologyWhy AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology
finance.yahoo.com - January 10 at 9:58 AM
Celgene Provides 2017 Preliminary Results & 2018 ViewCelgene Provides 2017 Preliminary Results & 2018 View
www.zacks.com - January 9 at 5:04 PM
Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology IndicationsWhy AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications
finance.yahoo.com - January 9 at 5:03 PM
AbbVie Expects Peak Sales of $7 Billion for ImbruvicaAbbVie Expects Peak Sales of $7 Billion for Imbruvica
finance.yahoo.com - January 9 at 5:03 PM
AbbVie’s Venclexta for Chronic Lymphocytic LeukemiaAbbVie’s Venclexta for Chronic Lymphocytic Leukemia
finance.yahoo.com - January 9 at 5:03 PM
Yes, Theres Hope for Celgene. Really.Yes, There's Hope for Celgene. Really.
finance.yahoo.com - January 9 at 5:03 PM
Celgene buys Impact Biomedicines in deal that could reach $7 billionCelgene buys Impact Biomedicines in deal that could reach $7 billion
www.bizjournals.com - January 9 at 9:50 AM
Healthcare Mergers and the JPM Conference; PayPal CEO Talks Bitcoin, M&A--ICYMIHealthcare Mergers and the JPM Conference; PayPal CEO Talks Bitcoin, M&A--ICYMI
finance.yahoo.com - January 9 at 9:50 AM
[$$] Celgene Can’t Cure the Biotech Blues[$$] Celgene Can’t Cure the Biotech Blues
finance.yahoo.com - January 9 at 9:50 AM
5 Things You Need to Know From Celgene's J.P. Morgan Presentation5 Things You Need to Know From Celgene's J.P. Morgan Presentation
finance.yahoo.com - January 9 at 9:50 AM
Moodys: US pharmaceutical companies cash holdings set to decline under new tax lawMoody's: US pharmaceutical companies' cash holdings set to decline under new tax law
finance.yahoo.com - January 9 at 9:50 AM
Celgene CEO on deal to acquire Impact BiomedicinesCelgene CEO on deal to acquire Impact Biomedicines
finance.yahoo.com - January 9 at 9:50 AM
Celgene to buy San Diego cancer-drug maker for as much as $7 billionCelgene to buy San Diego cancer-drug maker for as much as $7 billion
www.latimes.com - January 8 at 6:30 PM
Celgene to Buy Cancer-Drug Maker Impact for $1.1 Billion - BloombergCelgene to Buy Cancer-Drug Maker Impact for $1.1 Billion - Bloomberg
www.bloomberg.com - January 8 at 5:06 PM
3 Stocks to Watch on Monday: Celgene, LG Display and Takata Corp - Investorplace.com3 Stocks to Watch on Monday: Celgene, LG Display and Takata Corp - Investorplace.com
investorplace.com - January 8 at 5:06 PM
Celgene (CELG) Stock Rating Upgraded by Zacks Investment ResearchCelgene (CELG) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 8 at 3:58 PM
Celgene (CELG) Updates Q4 Earnings GuidanceCelgene (CELG) Updates Q4 Earnings Guidance
www.americanbankingnews.com - January 8 at 2:38 PM
Celgene (CELG) Issues FY18 Earnings GuidanceCelgene (CELG) Issues FY18 Earnings Guidance
www.americanbankingnews.com - January 8 at 2:38 PM
Biotech News: Celgene Corporation to Buy Impact BiomedicinesBiotech News: Celgene Corporation to Buy Impact Biomedicines
investorplace.com - January 8 at 10:49 AM
Stocks to Watch: Apple, Nvidia, Celgene, Caterpillar, Snap, Pandora, Kohl’s, LululemonStocks to Watch: Apple, Nvidia, Celgene, Caterpillar, Snap, Pandora, Kohl’s, Lululemon
blogs.wsj.com - January 8 at 9:31 AM
What’s News: Business & FinanceWhat’s News: Business & Finance
finance.yahoo.com - January 8 at 9:31 AM
PRESS DIGEST -Wall Street Journal - Jan 8PRESS DIGEST -Wall Street Journal - Jan 8
finance.yahoo.com - January 8 at 9:31 AM
3 Stocks to Watch on Monday: Celgene, LG Display and Takata Corp3 Stocks to Watch on Monday: Celgene, LG Display and Takata Corp
finance.yahoo.com - January 8 at 9:31 AM
Morning Movers: Celgene, Kohls Climb; Snap SlumpsMorning Movers: Celgene, Kohl's Climb; Snap Slumps
finance.yahoo.com - January 8 at 9:31 AM
Celgene to buy Impact Biomedicines for $1.1bn upfrontCelgene to buy Impact Biomedicines for $1.1bn upfront
www.ft.com - January 7 at 11:06 PM
Celgene to buy Impact Biomedicines for as much as $7 billionCelgene to buy Impact Biomedicines for as much as $7 billion
www.marketwatch.com - January 7 at 11:06 PM
Celgene Near Acquisition of Impact BiomedicinesCelgene Near Acquisition of Impact Biomedicines
finance.yahoo.com - January 7 at 11:06 PM
Celgene Will Pay Up To $7 Billion For Impact Biomedicines; Earnings Update DueCelgene Will Pay Up To $7 Billion For Impact Biomedicines; Earnings Update Due
finance.yahoo.com - January 7 at 11:06 PM
Celgene to Buy Cancer Drugmaker Impact for $1.1 Billion UpfrontCelgene to Buy Cancer Drugmaker Impact for $1.1 Billion Upfront
finance.yahoo.com - January 7 at 11:06 PM
[$$] Celgene to Buy Impact Biomedicines[$$] Celgene to Buy Impact Biomedicines
finance.yahoo.com - January 7 at 11:06 PM
Celgene to buy Impact Biomedicines for up to $7 billionCelgene to buy Impact Biomedicines for up to $7 billion
finance.yahoo.com - January 7 at 11:06 PM
The Wall Street Journal: Celgene to buy Impact Biomedicines for as much as $7 billionThe Wall Street Journal: Celgene to buy Impact Biomedicines for as much as $7 billion
www.marketwatch.com - January 7 at 9:12 PM
MEDIA-Celgene nears deal to buy Impact Biomedicines for as much as $7 billion -WSJMEDIA-Celgene nears deal to buy Impact Biomedicines for as much as $7 billion -WSJ
www.cnbc.com - January 7 at 5:19 PM
Celgene Nears Deal to Buy Impact BiomedicinesCelgene Nears Deal to Buy Impact Biomedicines
www.msn.com - January 7 at 5:19 PM
Celgene Nears Deal to Buy Impact Biomedicines for as Much as $7 BillionCelgene Nears Deal to Buy Impact Biomedicines for as Much as $7 Billion
www.wsj.com - January 7 at 5:19 PM
[$$] Celgene Nears Deal to Buy Impact Biomedicines[$$] Celgene Nears Deal to Buy Impact Biomedicines
finance.yahoo.com - January 7 at 5:19 PM
Celgene readies deal to buy Impact Biomedicines for as much as $7 billion - WSJCelgene readies deal to buy Impact Biomedicines for as much as $7 billion - WSJ
finance.yahoo.com - January 7 at 5:19 PM
Celgene readies deal to buy Impact Biomedicines for as much as $7 bln -WSJCelgene readies deal to buy Impact Biomedicines for as much as $7 bln -WSJ
finance.yahoo.com - January 7 at 5:19 PM
Celgene (CELG) Rating Lowered to Neutral at Bank of AmericaCelgene (CELG) Rating Lowered to Neutral at Bank of America
www.americanbankingnews.com - January 6 at 10:28 PM
Celgene (CELG) PT Set at $128.00 by MizuhoCelgene (CELG) PT Set at $128.00 by Mizuho
www.americanbankingnews.com - January 5 at 6:28 PM
Outspoken biotech CEO Paul Hastings leaves Peninsula company (Video)Outspoken biotech CEO Paul Hastings leaves Peninsula company (Video)
finance.yahoo.com - January 5 at 4:46 PM

SEC Filings

Celgene (NASDAQ:CELG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celgene (NASDAQ:CELG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celgene (NASDAQ CELG) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.